Merck & Co., Inc. (MRK) Earnings Call Transcript & Summary
February 3, 2026
What were the key takeaways from Merck & Co., Inc.'s February 3, 2026 earnings call?
In the fourth quarter of 2025, Merck & Co., Inc. reported total revenues of $16.4 billion, reflecting a 5% increase year-over-year. Earnings per share (EPS) were $2.04, demonstrating solid performance despite challenges in certain segments. Management provided 2026 guidance with expected revenues between $65.5 billion and $67 billion, indicating a modest growth outlook of 1% to 3%. This guidance includes a significant one-time charge related to the acquisition of Cidara Therapeutics, which is expected to impact EPS significantly in the near term.
What topics did Merck & Co., Inc. cover?
- Pipeline Expansion and Acquisitions: Merck highlighted the completion of the Cidara acquisition, which is expected to enhance its infectious disease portfolio, particularly with the long-acting antiviral MK-1406. CEO Rob Davis stated, "We now have line of sight to over $70 billion of potential commercial opportunity by the mid-2030s, $20 billion more than just a year ago."
- KEYTRUDA Performance: Sales of the KEYTRUDA family increased 5% to $8.4 billion, driven by strong demand in earlier-stage cancers. However, management noted a $200 million negative impact in the U.S. due to timing of purchases, indicating potential volatility in future quarters.
- New Product Launches: Merck's new product launches, particularly in cardiometabolic and respiratory segments, contributed to growth. The launch of OHTUVAYRE generated $178 million in sales, reflecting strong uptake post-acquisition of Verona Pharma.
- Guidance for 2026: Management provided a 2026 revenue guidance of $65.5 billion to $67 billion, which includes a one-time charge of approximately $9 billion from the Cidara acquisition. EPS guidance is set at $5 to $5.15, reflecting a cautious outlook amid expected generic competition.
- Challenges in Vaccine Sales: GARDASIL sales decreased by 35% to $1 billion, primarily due to lower demand in China and Japan. This decline raises concerns about the sustainability of revenue from this segment moving forward.
What were Merck & Co., Inc.'s February 3, 2026 results?
- Total Revenue: $16.4B (vs $15.6B est, +5% YoY)
- EPS: $2.04 (beat by $0.12)
- KEYTRUDA Sales: $8.4B (vs $8.0B est, +5% YoY)
- GARDASIL Sales: $1B (vs $1.54B prior year, -35% YoY)
- OHTUVAYRE Sales: $178M (new product launch)
- Animal Health Sales Growth: 6% (driven by livestock demand)
Merck's fourth quarter results reflect a company in transition, with a strong pipeline and strategic acquisitions aimed at long-term growth. However, the challenges in vaccine sales and the impending generic competition pose risks to the investment thesis. Investors should monitor upcoming regulatory milestones and product launches as potential catalysts for stock performance.
Earnings Call Speaker Segments
Peter Dannenbaum
executiveThanks, Shirley, and good morning to all of you. It's a pleasure to welcome you to the Merck & Co., Inc. Fourth Quarter 2025 Conference Call, broadcasting from Rahway, New Jersey, USA. Joining us today are Rob Davis, our Chairman and Chief Executive Officer; Caroline Litchfield, our Chief Financial Officer; and Dr. Dean Lee, President of Research Labs. Before we begin, I want to note that our GAAP results include items such as acquisition-related charges, restructuring costs and certain other items, all of which have been excluded from our non-GAAP results. You can find a reconciliation in our press release. I should also remind everyone that certain statements we make today may qualify as forward-looking statements under the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. These statements reflect the current beliefs of our company's management and carry significant risks and uncertainties. Should our underlying assumptions prove inaccurate or uncertainties come to pass, actual results could differ materially from those described in the forward-looking statements. Our SEC filings, including Item 1A in the 2024 10-K, lay out certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected in any forward-looking statements we make this morning. Merck & Co., Inc., Rahway, New Jersey, USA, assumes no obligation to publicly update any forward-looking statements. A slide presentation will accompany our speakers' prepared remarks during today's call. Those slides, together with the earnings release, today's prepared remarks and our SEC filings, are all available in the Investor Relations section of our company's website. With that, I'll hand the call over to Rob.
Rob Davis
executiveThank you, Peter. Good morning to everyone, and I appreciate you being on the call today. Everything we do is guided by our company's purpose of saving and improving lives. During 2025, we moved forward important programs spanning every stage of development, advancing our mission to bring transformative medicines and vaccines to patients worldwide and improve their health outcomes. The substantial progress we're achieving makes me very proud. Looking forward, we'll stay sharply focused on delivering breakthrough science and innovation, since that is what underpins the creation of sustainable long-term value for patients as well as shareholders. Our portfolio transformation is progressing steadily, and momentum keeps growing as we execute against our strategy. During 2025, several things went our way: we rolled out new products successfully, moved important clinical programs forward, and expanded what we offer in respiratory and infectious disease by bringing Verona Pharma and Cidara Therapeutics into the fold. Given all that momentum, a pathway is now visible toward a commercial opportunity worth more than $70 billion as we approach the middle of the next decade. That figure sits $20 billion higher than it was just twelve months earlier, and it's more than double the $35 billion consensus estimate for peak KEYTRUDA revenue in 2028. We aren't done yet, but this substantial headway bolsters a confidence I already held that we can keep growing sustainably once the KEYTRUDA LOE period has passed. Let me now move on to discuss our results and the preliminary guidance for 2026. For 2025, our growth reflects demand for an innovative lineup that includes KEYTRUDA, still reaching more cancer patients around the world, together with growing contributions from recent launches in cardiometabolic and respiratory, as well as vaccines, and a robust showing from Animal Health. We are positioned well for commercial success with key products in 2026, even while making significant investments to support our new product launches and a broader pipeline, a topic Caroline will cover shortly. Colleagues in research continue to deliver impressive progress across a wide and deep pipeline. I'll highlight a handful of important fourth-quarter developments in cardiometabolic and respiratory. During AHA, we shared Phase III data for enlicitide that underscore how an oral PCSK9 inhibitor could change practice. Heart disease remains the number one killer globally, and we're eager to bring forward a possible new therapy to address the cardiovascular epidemic. Turning to WINREVAIR, we reported Phase II top-line data from the CADENCE study that back its ongoing development in another form of pulmonary hypertension. Also, following our recent progress in HIV, we announced encouraging top-line results for islatravir in combination with doravirine among adults new to treatment who are living with HIV. Finally, we're delighted that enlicitide, along with sac-TMT, our investigational antibody drug conjugate targeting TROP2, each obtained commissioners' national priority vouchers from the FDA, which could accelerate review of these significant investigational candidates after submissions are made. We just completed the Cidara purchase, which fits well with what we already offer and builds on our long history in infectious disease. An antiviral candidate called MK-1406, formerly known as CD388, may be the first of its kind, providing durable protection, and it was created to help prevent influenza in individuals at elevated risk for severe complications. Among a sizable high-risk group, preventing influenza remains a significant unmet need, and the Phase II data were highly encouraging; we believe MK-1406 has the potential to generate over $5 billion in revenue and to act as a substantial growth driver in the latter part of this decade and into the following one. We're extremely excited to welcome the Cidara team aboard, and we eagerly anticipate advancing this first-of-its-kind preventive antiviral treatment. Today, our company is built around a key set of marketed medicines that address serious unmet medical needs. Beyond that, we're in the middle of reshaping what we offer, starting with launches from more than 20 prospective new growth drivers that carry the potential to push the practice of medicine ahead and transform patients' lives. Over the coming 2 years, 10 of those programs may see their clinical risk largely removed, and by the mid-2030s they will account for most of the $70 billion in commercial opportunity we see before adjusting for risk. Additionally, our forward-looking projections receive extra momentum thanks to anticipated vigorous expansion within Animal Health, the numerous early-stage initiatives slated to reach Phase II shortly, and further possible business development that is science-driven, rigorous, and accretive in value. We are entering an especially strong period for initial Phase III data releases on innovative prospects; during 2026, these encompass islatravir in combination with lenacapavir, which could become the first once-weekly oral regimen for individuals living with HIV; MK-3000, which may represent the first novel mechanism of action in 20 years for patients suffering from specific retinal conditions; and tulisokibart, for which we anticipate Phase III findings in ulcerative colitis along with Phase II results in additional autoimmune disorders. Looking ahead to 2027, we expect an even broader set of readouts. That includes Phase III data for sac-TMT, which in our view stands out as a differentiated TROP2 ADC. It also covers I-DXd, our B7-H3 antibody drug conjugate under study in small cell lung cancer and other tumor types, along with MK-1406 and several other key programs. So to wrap up: we're carrying out several product launches effectively, achieving meaningful clinical progress, and strengthening our pipeline through strategic business development. At the same time, we're making the investments required to support our success well into the future. Thanks to this progress and momentum, we're well positioned to keep delivering on our purpose for patients while generating lasting value for shareholders. I'd like to acknowledge our teams around the world and express appreciation for how dedicated they've been. There's still work ahead of us, but considering the steps we've taken, how far we've come, and the consistent discipline we keep applying, I have real confidence that we're set up well for the success that lies ahead. With that said, I'll hand things over to Caroline.
Caroline Litchfield
executiveThank you, Rob, and good morning. As Rob mentioned, during 2025 we achieved significant advances in helping patients and customers globally through our lineup of breakthrough medicines and vaccines. Growth came through for our business, powered by ongoing momentum in oncology and Animal Health, plus rising contributions from newly introduced products. These outcomes show the lasting resilience of our operations and provide us confidence regarding our guidance as we head into a stretch featuring numerous new launches. Our commercial and operational execution allow us to put resources into discovering, developing and launching the following generation of innovations, which will generate long-term value for patients, customers and shareholders. Now let's discuss our fourth quarter results. Revenues for the entire company reached $16.4 billion, up 5%, or 4% when you exclude foreign exchange effects. The revenue remarks that follow will be presented on an ex-exchange basis. Within oncology, sales for the KEYTRUDA family of products, encompassing KEYTRUDA and KEYTRUDA QLEX, rose 5% to $8.4 billion, with worldwide growth fueled by strong adoption in earlier-stage cancers and robust demand for metastatic indications. Use in tumors that mainly impact women, such as breast, cervical and endometrial cancers, remains a major driver of growth. Furthermore, we observed greater utilization of KEYTRUDA alongside PADCEV in locally advanced or metastatic urothelial cancer. Within the U.S., growth took a hit of roughly $200 million because of purchase timing. We're happy with the favorable provider response after the recent introduction of KEYTRUDA QLEX. As anticipated, sales during the quarter came to $35 million. We anticipate making a bigger difference for patients and health care systems once a permanent J-code is implemented in the U.S., which we still expect to happen at the start of April. Our wider oncology portfolio posted yet another quarter of robust growth. In particular, WELIREG sales climbed 37% to $220 million, mainly driven by greater use among certain patients with previously treated advanced renal cell carcinoma in the U.S., along with continued adoption from ongoing launches in certain international markets. We anticipate potentially helping more patients with renal cell carcinoma after positive data from the LITESPARK-011 and LITESPARK-022 studies; in vaccines, GARDASIL sales totaled $1 billion, a decline of 35%, caused by weaker demand in China and Japan. Other international markets expanded 8%, helped by purchase timing. Within the U.S., sales rose 7%, primarily because of price. In pneumococcal, the CAPVAXIVE launch keeps advancing nicely with sales of $279 million, fueled by demand from both retail pharmacies and non-retail customers, including adoption from heightened seasonal immunization activity in the U.S. In RSV, ENFLONSIA sales reached $21 million. Early adoption has been limited by a lower-than-expected infant immunization rate, combined with elevated levels of total RSV monoclonal antibody inventory in the market. In cardiometabolic and respiratory, WINREVAIR keeps delivering a positive effect for patients with pulmonary arterial hypertension. Global sales hit $467 million, reflecting the ongoing strong demand for this important treatment. Within the United States, prescriptions were written for over 1,500 patients who were new to the product, and more than 27,000 prescriptions in total were filled. Additionally, we observed a rise in the share of patients whose background treatments don't involve a prostacyclin. Beyond the U.S., our work to obtain approvals and reimbursement keeps moving forward. Building on the successful American launch of OHTUVAYRE brings us excitement — it's a maintenance therapy for adults living with COPD that works through a novel mechanism of action. Sales during the quarter reached $178 million, which reflects revenues recorded after the Verona acquisition closed on October 7; we achieved robust expansion in new patient starts along with the total number of patients being treated. Physicians also wrote prescriptions for OHTUVAYRE for a greater share of their patients, and the overall count of prescribing physicians went up. Keep in mind that we anticipate seasonality early in the year when Medicare deductibles get reset. Investments are being made by us to get the most out of the ongoing U.S. launch, and we look forward to helping more adults with COPD. Another quarter of strong growth came from our Animal Health business, with sales up 6%. Livestock sales rose 9%, powered by greater demand across every species. Companion animal sales stayed flat, since gains from new product launches were canceled out by fewer vet visits. I'll now take you through the rest of our P&L, and everything I say will be on a non-GAAP basis. Gross margin came in at 79.7%, down 1.1 percentage points, driven by higher inventory reserves and partly offset by a favorable product mix. Operating expenses fell to $6.8 billion. A $150 million charge tied to an agreement with Dr. Falk Pharma for acquiring sole global rights to MK-8690 was less than the $700 million in business development charges from a year ago. If you set aside those charges, operating expenses held steady, mirroring greater investment behind our innovative pipeline and key growth drivers, offset by gains from our multiyear optimization initiative. Other expense totaled $226 million. Our tax rate stood at 15.4%. All together, earnings per share came to $2.04. Let's shift now to our 2026 non-GAAP guidance. Revenue is expected to land between $65.5 billion and $67 billion, which means growth of 1% to 3%, and that includes a roughly 1 percentage point positive effect from foreign exchange based on mid-January rates. We're assuming a gross margin of approximately 82%. Operating expenses are projected to be somewhere between $35.9 billion and $36.9 billion, and that figure contains a onetime charge of roughly $9 billion connected to the Cidara acquisition. One reminder: our guidance doesn't factor in any additional significant potential business development transactions. Other expense of approximately $1.3 billion reflects financing costs for Cidara and Verona. For the full year, we're assuming a tax rate of between 23.5% and 24.5%, which captures the nontax deductible onetime charge for Cidara; we also assume approximately 2.48 billion shares outstanding. Putting it all together, we expect EPS of $5 to $5.15, with a midpoint of $5.08, and that includes an approximately $0.10 positive effect from foreign exchange based on mid-January rates. If you take out roughly $3.65 per share tied to the upfront charge from buying Cidara, plus $0.30 per share of continuing costs to move MK-1406 forward and the finesta transaction, we land at a midpoint of $9.03. A few things are worth keeping in mind as you build your models. Growth is what we anticipate delivering in 2026, powered by rising contributions from products we've recently launched, along with sustained momentum in oncology and Animal Health, even with a roughly $2.5 billion headwind stemming from generic competition, IRA price setting and the restructured Koselugo agreement. The JANUVIA family, BRIDION and DIFICID are where generic competition mainly bites. On top of that, we anticipate notably weaker LAGEVRIO sales because demand keeps softening. Shifting now to capital allocation, our strategy there hasn't changed. Investments in the business come first so we can fuel near- and long-term growth, and that covers new product launches along with our strong pipeline. The dividend stays a commitment, and our aim is to raise it over time. Business development also ranks as a high priority. Should science and value line up, we're well positioned to go after further transactions. Built into our guidance is about $3 billion for share repurchases, and we stay committed to preventing excess cash from accumulating on the balance sheet. In closing, we stepped into 2026 feeling confident about our business outlook, thanks to worldwide demand for our innovative medicines and vaccines, which includes the encouraging progress across our many launches and the upcoming clinical milestones from our promising pipeline. Our long-standing dedication continues: bringing forward medically significant innovations that let us deliver value to patients, customers and shareholders far into the future. With that, I'll hand the call over to Dean now.
Dean Li
executiveThank you, Caroline. Good morning to all of you. We keep seeing forward momentum throughout programs that stretch across several therapeutic areas. During today's call, I'll walk through updates for cardiometabolic and respiratory, then infectious disease and oncology programs, and I'll wrap up by summarizing key highlights from 2025 along with milestones we expect later this year. Let's begin with the strides made in our cardiometabolic and respiratory pipeline and programs. Enlicitide, the oral PCSK9 inhibitor we are investigating, was engineered to achieve antibody-like efficacy while providing a convenient option taken orally just once per day, with the possibility of helping tackle the CV epidemic. Findings from 2 Phase III trials that assessed enlicitide in treating adults whose LDL cholesterol is elevated were shared at the American Heart Association Scientific Sessions in November. In the CORALreef Lipids study, which enrolled a broad population of adults who had or were at risk for atherosclerotic cardiovascular disease while receiving background lipid-lowering therapies or who could not tolerate statins, as well as the CORALreef HeFH study involving adults with familial heterozygous hypercholesterolemia, enlicitide produced statistically significant and sustained decreases across several atherogenic factors, among them LDL-C, ApoB, non-HDL-C and Lp(a). Results from CORALreef HeFH appeared in the Journal of the American Medical Association, while those from CORALreef Lipids have been accepted by the New England Journal of Medicine; furthermore, favorable data from a third Phase III trial, CORALreef AddOn, which examines enlicitide against other oral non-statin therapies in adults with hypercholesterolemia who are on a statin, are scheduled for presentation at the American College of Cardiology Congress in March. Our Phase III CORALreef outcome study continues and enrollment is now complete. Regarding WINREVAIR, we keep advancing our regulatory strategy worldwide. In the past month, the European Commission granted approval for a broader indication covering adults who have pulmonary arterial hypertension with WHO functional Class II, III and IV, supported by the Phase III ZENITH study. We are also pressing forward with evaluation of WINREVAIR for another indication tied to progressive vascular remodeling and resistance. The Phase II CADENCE study hit its primary endpoint, delivering a statistically significant and clinically meaningful lowering of pulmonary vascular resistance versus placebo among adults with combined post and precapillary pulmonary hypertension resulting from heart failure with preserved ejection fraction; this evidence confirms proof of concept and will guide a Phase III program for that population. Full results are likewise set to be shared at the American College of Cardiology Congress in March. Turning now to infectious disease. During the last month, we closed our purchase of Cidara Therapeutics. The magnitude of the seasonal flu outbreak currently underway in the Northern Hemisphere underscores the danger influenza presents, the related strain placed on health care systems and, crucially, the necessity of better prevention approaches, particularly for people facing elevated risk of severe complications. Enrollment for the Phase III ANCHOR trial, which is assessing MK-1406 — a potentially first-in-class, long-acting, preventative, strain-agnostic antiviral featuring a differentiated mechanism of action — wrapped up during November across the Northern Hemisphere. At the same time, we intend to sign up participants throughout the Southern Hemisphere so that we can gather a strong data set covering a wide patient population, among them adults with compromised immune systems, and obtain further information regarding diverse strains in circulation. Additionally, the study needs to include people who have received flu vaccinations as well as those who have not. Now on to HIV. During November, we reported favorable top line findings from a Phase III trial of our investigational once-daily, single-tablet, 2-drug combination of doravirine plus islatravir — a next-generation nucleoside analog that works through translocation inhibition — in adults with HIV-1 infection who had not previously received treatment. No other 2-drug regimen lacking an HIV integrase strand transfer inhibitor has shown non-inferior efficacy and safety when compared with the widely prescribed 3-drug INSTI-based regimen, Biktarvy. Given its strong antiviral activity and high barrier to resistance, we aim for islatravir to become a novel anchor medicine within numerous 2-drug treatment regimens, delivering fresh daily and weekly choices for individuals living with HIV. Full results are set to be shared at a medical congress taking place soon. Shifting to oncology. Evidence kept showing how KEYTRUDA makes a difference in treating a broad range of cancers. Regarding bladder cancer, 2 significant recent milestones occurred. To begin with, the FDA gave the green light to KEYTRUDA and KEYTRUDA QLEX, both paired with PADCEV as neoadjuvant therapy and then continued following cystectomy as adjuvant therapy, for adults battling muscle invasive bladder cancer who cannot receive chemotherapy containing cisplatin, based on the Phase III KEYNOTE-905 trial; this marks the initial PD-1 inhibitor plus antibody drug conjugate regimen cleared for this patient group. Next, we disclosed favorable top line data from the Phase III KEYNOTE-B15 study. When administered as neoadjuvant and adjuvant therapy, the pairing of KEYTRUDA with PADCEV produced statistically significant and clinically meaningful gains in event-free survival, overall survival and pathologic complete response rates relative to neoadjuvant chemotherapy plus surgery. This stands as the first and only perioperative immunotherapy plus ADC regimen proven to prolong survival among cisplatin-eligible patients suffering from muscle-invasive bladder cancer. Complete results will be unveiled later this month during the ASCO Genitourinary Cancer Symposium. Taken together, these regimens could give patients with muscle-invasive bladder cancer — whether or not they qualify for cisplatin chemotherapy — a KEYTRUDA-based choice. We currently have 3 more Phase III trials underway examining KEYTRUDA in various stages of bladder cancer, specifically KEYNOTE-992, KEYNOTE-866 and KEYNOTE-676; working alongside Moderna, we just shared 5-year follow-up results from the Phase IIb KEYNOTE-942 study, which looked at intismeran autogene, an individualized neoantigen therapy candidate, combined with KEYTRUDA among patients having high-risk Stage III or IV melanoma after complete resection; in that follow-up analysis, the trial showed a sustained gain in recurrence-free survival, with a 49% lower risk of recurrence or death versus KEYTRUDA by itself, expanding upon the primary and 3-year analysis previously reported from the study. Our Phase III INTerpath-001 study, which focuses on adjuvant melanoma, continues and has completed patient enrollment. Back in November, the European Commission gave the green light to a subcutaneous shot combining pembrolizumab with berahyaluronidase alfa, sold across the EU under the name KEYTRUDA SC, covering all 33 indications KEYTRUDA has for adults. In Europe, this stands as the first and only subcutaneously delivered immune checkpoint inhibitor, able to be given either in 1 minute on a 3-week cycle or in 2 minutes on a 6-week cycle. We are folding this faster subcutaneous pembrolizumab option into how we run our clinical development efforts. Turning to KANDLELIT-007, that's a Phase III trial looking at calderasib — an oral, selective KRAS G12C inhibitor still under investigation — paired with KEYTRUDA QLEX as first-line therapy for patients whose advanced or metastatic non-squamous non-small cell lung cancer carries a KRAS G12C mutation. Come December, during the American Society of Hematology Annual Meeting, we showcased advances throughout our hematology pipeline, with favorable results across several candidates: MK-1045, an investigational CD19 CD3 T-cell engager for adults battling relapsed or refractory B-cell acute lymphoblastic leukemia; nemtabrutinib, a noncovalent BTK inhibitor under investigation for chronic lymphocytic leukemia or small lymphocytic lymphoma patients; plus bomedemstat, an investigational LSD1 inhibitor for polycythemia vera patients who don't respond to or can't tolerate cytoreductive therapy. Beyond that, 2 Phase III studies are currently underway testing bomedemstat in essential thrombocythemia, which is an orphan disease. The year 2025 brought notable pipeline momentum, with favorable results shared from 18 Phase III trials and 21 Phase III trials launched, covering cardiometabolic and respiratory, immunology, infectious disease, oncology and ophthalmology.
Dean Li
executiveAdditionally, we obtained clearances from regulators spanning various therapeutic fields, such as oncology with KEYTRUDA QLEX and further regimens built around KEYTRUDA, covering patients who cannot receive cisplatin with MIBC as well as locally advanced head and neck squamous cell carcinoma. On the infectious disease side, ENFLONSIA, our long-acting monoclonal antibody designed to prevent respiratory syncytial virus, lower respiratory tract disease among infants born during or entering their first RSV season. Then in cardiovascular, the label update for WINREVAIR in PAH. Lastly, we keep executing our one pipeline strategy by drawing on our clinical know-how and strong business development strengths. Bringing Verona Pharma and Cidara Therapeutics into the fold strengthens our pipeline and moves forward strong candidates that may help patients facing significant unmet needs. Building on the momentum we generated in 2025, we look ahead to a variety of milestones across many therapeutic areas in the coming months, including in oncology — the February 20 PDUFA date for specific patients with platinum-resistant recurrent ovarian cancer, which is based on the KEYNOTE-B96 trial. We're going to share detailed results at ASCO GU. Those findings cover WELIREG, which is our first-in-class oral HIF-2 alpha inhibitor, in adjuvant settings and in specific advanced renal cell carcinoma types, drawing on the Phase III LITESPARK-011 and LITESPARK-022 trials. We'll also present data for KEYNOTE-B15 in cisplatin-eligible MIBC patients. Turning to HIV, there's a PDUFA date of April 28 for doravirine and islatravir, a 2-drug regimen taken once daily by mouth. We also expect top line data from the Phase III ISLEND-1 and ISLEND-2 trials, which are evaluating islatravir and lenacapavir as a once-weekly oral 2-drug regimen, and that work is in collaboration with Gilead. Starting with cardiometabolic and respiratory: at ACC this March, we'll present detailed results for WINREVAIR, coming out of the Phase II CADENCE study, which looked at a subset of patients with pulmonary hypertension caused by left heart disease, along with findings for enlicitide from the Phase III CORALreef AddOn trial. Then in immunology, there's data on tulisokibart, our TL1A inhibitor, drawn from the Phase III ATLAS UC trial in ulcerative colitis as well as the Phase II ATHENA study in SSc-ILD. And last, in ophthalmology, we have results from the Phase III BRUNELLO study of MK-3000, our novel Wnt agonist under evaluation for diabetic macular edema, plus the Phase II RIOJA study of MK-8748, our potential first-in-class Tie2 agonist VEGF inhibitor being assessed as a treatment for certain retinal diseases. We keep pushing our diversified pipeline forward, centered on executing quickly and rigorously. I anticipate sharing more updates throughout 2026; and at this point I hand the call back to Peter.
Peter Dannenbaum
executiveThanks, Dean. Shirley, let’s open it up for questions now. We do have a firm cutoff at 10:00 a.m. today, so please, I’d ask that analysts keep to a single question.
Mohit Bansal
analystCongratulations on the pipeline advances. Could you perhaps go deeper on CD388 and what an interim could mean here? This flu season looks like a heavy one, so it seems event rates might be accumulating faster than anticipated in ANCHOR. Still, I'd like to hear how you think about completing the whole study. Does that rest on producing solid data across two geographies and two seasons, or on what you're observing regarding event rates in the trial that's underway? Also, ought we to look for an interim readout in March, later than March, or not at all?
Dean Li
executiveDean here. I agree that your observation about this being a comparatively harsh season, particularly for those of us in the Northeast dealing with influenza, shows just how significant this month may prove. Enrollment for the Northern Hemisphere is now finished. As I noted in the prepared remarks, let me stress that we are simultaneously enrolling in the southern hemisphere. The trial is event-driven. I want the appropriate sample size. I want the assumptions behind the powering. Above all, though, I must ensure I have robust data across a set of subpopulations that matter for the eventual label. So right now, we haven't discussed any communication plans after IA, yet we're enthusiastic about this first-in-class, once-per-season, strain-agnostic antiviral agent, which I believe will be needed more and more as time passes.
Akash Tewari
analystGiven some of the emerging data coming out of China, do you have any plans to look at sac-TMT in a first-line NSCLC setting for patients with low PD-1 expression, or in a head-to-head study against the KEYNOTE-189 regimen? I'm somewhat curious why your TROP2 development strategy appears comparatively conservative next to what AstraZeneca and Daiichi are pursuing, particularly if your asset is differentiated?
Dean Li
executiveThanks so much for asking that. As we've stated many times, in our view this is a workhorse ADC; we also believe that — when I look at the HER2 space and I sit there and think, you simply alter the linker and the payload and suddenly you get very different readouts from an antibody drug conjugate. And so in our view sac-TMT could potentially be a best-in-class TROP2 directed ADC. On the ambition point you raise, I'd note we have 16 Phase III studies, 11 that we consider first-in-class, while the remaining 5 are differentiated; so I'd say our sac-TMT program is very ambitious. Regarding — your specific question, regarding non-small cell lung cancer and breast cancer, we believe our approaches are differentiated from others'. But most important, we also have it in tissue types and tumor types where we hope to be first. So I'd push back a little on the characterization that our program is not robust and ambitious. We have 16 Phase III studies.
Alex Hammond
analystRight now, the consensus view is that KEYTRUDA's U.S. LOE lands in '28. That said, Merck's SEC filings point to the possibility of 2 more patents running out in '29. So my question is, what's the right way to model the IP run rate for KEYTRUDA? And how should we think about when QLEX ramps relative to when the KEYTRUDA IV biosimilar comes in?
Rob Davis
executiveYeah. Appreciate the question. If you look at where things stand on KEYTRUDA's intellectual property, back when the initial invention was submitted to the patent office for approval, the patent estate behind that original innovation was actually made up of 4 patents. The compound patent is one of them, and it runs out in December of 2028. Of the other two, a method of making patent has actually been stretched to May of 2029; the second, a method of use patent, reaches November of 2029. So when we examined this, our early assumptions were conservative and always tied to the compound patent, though always with the intention of defending the full patent estate. What I think has shifted over time is that with case law developing, our confidence in defending those 2 extra patents has increased. That means there's a possibility you'll see protection lasting through either May or November of 2029. For planning purposes, we still assume 2028, since I consider that the conservative assumption; we'll need to watch how it plays out. And I'd also point out that the IRA hits us starting in early 2029. On QLEX adoption, our view remains that we'll reach 30% to 40% uptake by the time 2028 arrives, and we'll push that as far as we can. And as you're aware, our pricing was set to encourage the shift from KEYTRUDA IV to QLEX. So that effort continues. That approach is already in motion. And honestly, whether it lands in '28 or '29, the strategy we're pursuing stays the same.
Evan Seigerman
analystI'd like to talk about the HIV information you brought up. Could you put into context why a dual regimen matters compared with the standard of care, bictegravir or Biktarvy? And also, what are you hearing more generally about unmet need for a two-drug approach versus the three-drug standard of care?
Dean Li
executiveYes, thank you so much for asking that. As you point out, islatravir has us quite enthusiastic, since we genuinely view it as a next-generation nucleoside analog. Its distinct translocation inhibition mechanism yields strong potency along with a substantial barrier to resistance. When it comes to two drugs versus three drugs, options have always been needed in different forms. You can already observe a two-drug option on the market alongside three-drug options, and this patient population tends to switch treatments quite a bit as a general matter. So being able to provide a different repertoire of compounds, particularly if the integrase can be spared, could be quite meaningful. For certain individuals, that's frequently considered through the lens of metabolic and long-term concerns associated with HIV therapy. So I believe there will be enthusiasm around a two-drug combination that lacks an INSTI backbone. Just as importantly, I want to be clear that we're pursuing a two-drug regimen as the first Q-weekly offering, and we have one together with our partner, Gilead, plus another one with <<inaudible>>. So all of those — that two-drug for daily use, and also that two-drug for weekly use — there's no weekly three-drug or two-drug option. So we see a significant opportunity for patients to have a Q-weekly choice. And lastly, we have a Q-monthly oral prep. No other Q-monthly oral prep exists. Even though it isn't islatravir, it's a related compound, MK-8527.
Steve Scala
analystHere's a broader question for Rob. During 2025, Merck hit the sales guidance it set at the beginning of the year, and you contended with GARDASIL headwinds throughout those 12 months. Yet every company, in any given year, runs into some difficulties. So chances are this pattern will be the norm, not the anomaly. Merck also has several growth products. So in what could be a standard year, Merck's growth was minimal. And for 2026, you're once again targeting only slight top line growth, with the KEYTRUDA LOE still roughly 2 years away. So my question is: should we anticipate this from Merck moving forward — a business that expands modestly when conditions are favorable and faces heavy pressure when they aren't? Or is Merck capable of delivering sustainable, robust sales growth across the coming decade, no matter what unavoidable hurdles arise?
Rob Davis
executiveYes. Steve, I appreciate that question. I'd simply stress again, as we look ahead — and I believe this is what comes through in our confidence and in why we expect to be a strong growing company over time — I'm not certain I share your framing that we'll be a modest growing company each year, or less, depending on circumstances. That, to me, takes 1 year out of context. If you examine the longer horizon, though, that $70 billion of potential we hold is significant, considering that it's more than double what KEYTRUDA will reach at its consensus peak in '28 of $35 billion. And crucially, it's $20 billion higher than where we stood, powered by what is likely the broadest and widest pipeline we've had in years. So our confidence in our capacity for sustainable growth once we're past the LOE is greater than it has ever been, and we're not finished. We have early-stage pipeline assets that we believe will read out over the next 2 years and will let us keep bringing some of those assets into this period, along with further business development. And as you're aware, none of this counts the Animal Health business, which we expect to more than double out to the mid-2030s, nor the base of KEYTRUDA over time. So I think that matters to grasp. Another point I'd emphasize: of that $70 billion, we're going to derisk substantially all of it by the time we reach the end of 2027. So by the time you get out to 2027, you'll know the portfolio that will drive our growth into the next decade — and I think that's also important as people begin to want clarity on the long-term future. One more point I'd like to make: take 2025 as a case in point — what we witnessed during the quarter is genuinely a robust growth picture. And looking ahead, once you strip out the LOE window we flagged involving JANUVIA, DIFICID, and BRIDION, along with LAGEVRIO and Koselugo, our guidance actually calls for growth, I believe, somewhere in the 4% to 7% band, or approximately 5% to 8%, across time — which is, in fact, fairly solid growth. And I'd say that's really where the emphasis belongs: what's the durable, strategic expansion of those assets over the long haul, rather than the one-off, nonstrategic LOEs we're up against in this year.
James Shin
analystThis next one is for Dean. Regarding CADENCE at the ACC presentation, could you help us establish a baseline for what we ought to expect and what we shouldn't expect to find out? Additionally, is there any information on which possible endpoints might be investigated in the Phase III trial for CpcPH stemming from HFpEF?
Dean Li
executiveYour audio cut out briefly there, so I'm hoping I can still address your questions. My expectation is that we will present the data from that Phase II study. There is a primary endpoint, and there are also significant secondary endpoints that we will share as well. Regarding what you just inquired about concerning a future Phase III that we have talked about, those conversations with the FDA are ongoing right now; and as a broad kind of comment, in general, we will need to consider matters such as functional activity. Frequently there are clinical events that matter. Biomarkers will be part of it; however, it's going to be crucial to get alignment with the FDA since in this group of patients, which ought to be an orphan indication population, we will need to establish a baseline for how one approaches the outcomes along with the primary and secondary endpoints; but we are keen to share that data at ACC, and we keep holding discussions with the FDA while we essentially characterize a new population that this drug will be aimed at. So a number of the questions you raised concerning the endpoints are matters that are being actively discussed at this time.
Carter Gould
analystOne more for Dean. I understand that with your TL1A, the close-term priority is ATLAS UC. Yet at the same time, we're watching the established IL-23 companies ramp up with various kinds of combinations and multispecifics quite fast, pushing harder through fairly large partnerships. So once more, while acknowledging ATLAS UC is the near-term priority, how does Merck view the significance and the pace it might need to chase combinations following those data later this year?
Dean Li
executiveYeah. Your question is great, so let's all get on the same page. Basically, within this space, TNF and IL-23 have been dominant; and the key issue is whether a third node or third class exists, namely TL1A. Our goal is to be the first and best-in-class TL1A. We're testing it across 6 diseases; but as you point out, ulcerative colitis and Crohn's disease are the ones advancing very fast. Should those succeed, as with any immunology indication, the matter turns to patient populations, other diseases. After that, folks will begin discussing combinability. They'll discuss it in terms of 2 distinct antibodies. They'll discuss bispecifics. And more and more, they'll discuss orals. And I can tell you that the idea of intending to be first and best, plus having a strong plan for being next, fits together well. But that's likely something I'd rather not state on a public call right now.
Geoff Meacham
analystHere's another one about WINREVAIR. You're approaching the two-year mark since launch. Could you discuss what you're seeing in terms of how long patients stay on treatment, or perhaps the real-world safety and tolerability profile? Is anything showing up differently compared with Phase III? And past CADENCE, how are you approaching other pulmonology indications where this mechanism might play a role?
Dean Li
executiveI'll take that first. A great many questions came in from a scientific perspective. What I'd really like to stress is that WINREVAIR is changing the standard of care in PAH. That's happening because of a differentiated pathway and a differentiated molecule. Every other drug out there, if you examined them, you'd call them classic vasodilators; this one reaches the underlying biology by way of the genetics. The way I'd actually start to think about WINREVAIR and what it might be doing for right heart failure and PAH is comparable to what Merck demonstrated for ACE inhibitors years ago in relation to left heart failure. So when that question comes to me, my feeling is that we are already reshaping the standard of care. My expectation is that guidelines will emerge and will be informed by those clinical data. As for adverse effects and long-term treatment, I had actually just returned from touring sites in Texas, and they are quite bullish not only on the drug, but also on its sustainability and on the notion that suddenly, in their thinking, they had started talking about blunting cardiac remodeling. So that's where we are with this; we're making progress in relation to heart failure, just as the earlier question did in CADENCE. But I love your question, because so much of it centers on what stress is being placed on the right heart; and as you note, there could be pulmonary indications involving pulmonary hypertension where we need to think carefully about where and when to use this drug; yet there are investigators who have raised that question with us. They also raise the point that when you look at PAH, there are different patient populations, but a substantial number of them have connective tissue disorders. So they immediately say connective tissue disorders are also tied to pulmonary fibrosis and other pulmonary disease; so those are discussions, and those are things people are exploring right now, and we will see some of those data, and that will shape our decisions going forward.
Rob Davis
executiveAlso, Jeff, let me jump in here. If you consider our current position, and just so you get a feel for the scope, more than 110,000 prescriptions have been filled. At this point, over 9,100 patients have begun treatment. And looking at it, our overall compliance remains pretty high. We're observing a gradual uptick in discontinuation rates. But honestly, that's broadly consistent with, or a touch better than, what we see with other PAH products. So we're feeling good about that. Then when it comes to safety, we remain highly confident in the safety profile, and it aligns with the label. I'd also mention now, as you've observed in what we've shared regarding HYPERION, as well as ZENITH, and then going back to STELLAR, and then what we've also presented is some long-term data from SOTERIA — throughout all of those, the safety profile is very consistent. So we feel quite good about where we stand with compliance, where we stand with safety. Everything is progressing as you'd anticipate.
Umer Raffat
analystRob, today I'm attempting to weigh two things against each other. On one side, you're presenting a $70 billion revenue opportunity from the current pipeline that isn't risk-adjusted, plus the entire prior history of roughly $5 billion revenue opportunities picked up for about $10 billion or less. On the other side, there's that big deal recently covered in the press. I'm just trying to reconcile all of it.
Rob Davis
executiveYes. Umer, thanks for raising that. Naturally, we never discuss or guess about market rumors. If you examine our BD strategy and our current position, I'd begin by noting what you yourself pointed out: with the $70 billion of commercial potential we've put forward, and given that this figure sits $20 billion above where it stood 12 months ago, I take a great deal of pride in the headway we're making, and that's exactly why my confidence runs so high. And clearly, additional time remains for us to keep doing more — both when it comes to pushing forward our early-stage pipeline, which we believe can make a difference in this space, and when it comes to bringing in further assets via BD, something we've said we remain quite eager to pursue. As for our areas of focus, they're exactly what we've consistently described: opportunities featuring meaningful scientific advancement, targeting an unmet need that fits our strategy, and — crucially — where value creation is visible. When those elements line up, we act, though we've always acted with discipline. That's been evident in every deal we've completed, and it will stay that way going forward. Clearly, deals as large as $15 billion represent our sweet spot. That said, as we've also made clear, for the right scientific deal, we'd go bigger — while applying the identical methods, discipline, and approach we've brought to everything we've done so far.
Chris Schott
analystRegarding MK-3000, clearly this is a novel mechanism, yet it also appears among your key near-term products intended to reduce risk on that $70 billion. Could you help frame what instills such confidence in this asset and how big an opportunity you foresee, assuming some positive data arrives this year?
Dean Li
executiveHow large the opportunity might be, I'll leave for others to address, but diabetic macular edema and wet age-related — pardon me, AMD and DME — are truly significant indications, and there are important molecules already available for them; every one of those relies on vascular endothelial growth factor. The pathway here is the first grounded in the genetics of vascular stability within the eye, and ours is the first agonistic antibody directed at it. So we're quite eager to learn whether this mechanism proves effective, since it would be the first non-vascular endothelial growth factor agent moving toward the indications of age-related macular degeneration and diabetic macular edema. Looking back historically, as many as 40% of individuals respond suboptimally to VEGFs. That strikes us as a meaningful opportunity; however, I'd also like to ensure people appreciate that even among patients who do respond to vascular endothelial growth factor, MK-3000 might likewise become part of the repertoire used in their treatment.
Rob Davis
executiveAnd perhaps I could just chime in, Chris, with a few additional perspectives regarding the potential of this market. As you're aware, when examining the situation with diabetic macular edema, roughly 1.6 million individuals in the United States currently have DME. Among vision loss cases caused by diabetes, it ranks as the primary driver. Furthermore, I would note that with wet AMD, there are another 1.5 million patients across the United States. So when you consider the entirety of that market, it amounts to approximately $15 billion. And as Dean mentioned moments ago, between 30% and 40% of patients respond only partially or do not respond whatsoever to anti-VEGF therapy; therefore, the chance to introduce a novel mechanism into this area is very significant. The sole additional point I would make is that although your discussion concerns MK-3000 in DME at present, we are likewise conducting studies of it in wet AMD in RVO. And crucially, we possess MK-8748, the novel bispecific antibody that agonizes Tie2 while inhibiting VEGF. That has us quite enthusiastic. It is truly the pairing of those two assets that leads us to believe this represents an opportunity exceeding $5 billion going forward. And I would characterize it as likely among the more underappreciated areas, in my view, on the part of the Street and regarding what this could genuinely become.
Peter Dannenbaum
executiveGreat. We're going to try and squeeze in one more question, please, Shirley?
Daina Graybosch
analystLet's wrap up with the sac-TMT topic. Could you give us an update on where your biomarker approach stands, now that a TROP2 ADC rival just said it's shifting certain Phase III primary endpoints to focus on TROP2 expressers? I'm aware you have something in the works — will that show up in any Phase III trials?
Dean Li
executiveSure. My answer now is basically the same one I gave a few years back: we believe sac-TMT can be best-in-class, yet you also need to target the correct tumor types and pursue the correct strategy within them. Some tumor types, in our view, won't require a biomarker. At the same time, we think certain settings will call for one, particularly when you consider how strong the comparator is that you must go up against. So much of this depends on the tumor's context, plus which other therapies exist and how tough the bar set by that comparator is to clear.
Peter Dannenbaum
executivePerfect. Daina, I appreciate it, and I'm grateful to everyone for spending part of your morning with us. Should anything else come up that you'd like to ask about, the IR team is available to help. Be well.
Operator
operatorThanks for joining, everyone — that brings the call to a close. We appreciate everyone taking part. You're free to hang up at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Merck & Co., Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Merck & Co., Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck & Co., Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.